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As of 2011, cancer was the leading
cause of death in the United States,
second only to heart disease. Cancer is
often referred to as being “immortal”
because of its ability to divide a seemingly
infinite amount of times. Normal cells
are limited in the number of times they
can divide by the caps on the ends of
their chromosomes, called telomeres.
These caps are supposed to become
degraded over time, signaling the cell
to die when they become too short. As
cancer continues to become an everincreasing threat to human health, the
race is on to find an effective telomerase
inhibitor. If telomerase is inhibited, the
telomeres of cancer cells can no longer be
elongated. Stripped of their immortality,
cancer cells will eventually undergo
apoptosis, or controlled cell death.
This inhibitor has to be able to destroy
cancer cells while leaving healthy cells
unharmed. Research has uncovered that
the molecular structure of a compound
known as BIBR 1532 has proven to be
an effective telomerase inhibitor. Current
research has shown that BIBR 1532
inhibits telomerase by preventing it from
extending the copied strand any further
than the length of the original
strand of DNA.
Research has not yet discovered what
portion of BIBR 1532 causes it to
be such a good telomerase inhibitor,
though several theories do exist. The
most popular theory, supported by past
research, is that three structures present
in the BIBR molecule contribute to its
efficacy: an aromatic ring containing a
carboxylic acid and a conjugated amine
group. This is the theory on which my
current research is based upon and
served as the basis for the synthesized
compounds. Three compounds were
made via the synthesis of cinnamic
acid and contained the aforementioned
substructures found in BIBR 1532. The
basic skeleton of the chemical structure
was created from cinnamic acid, due to
its natural ability to inhibit telomerase.
Using the reactive properties of cinnamic

acid, several different substituents were
added while maintaining the three key
structures. The Schotten-Baumann
protocol was utilized to synthesize
the final product, the purity of which
was tested using HNMR and CNMR
techniques. The results of this experiment
were three novel chemical compounds
that each contains an aromatic ring, a
carboxylic acid, and a conjugated amine
group. These compounds also possess the
natural anticancer properties of
cinnamic acid.
These three compounds are currently
undergoing testing for telomerase
inhibition using the Telomerase Repeat
Amplification Protocol assay. The
compounds will be tested on prostate
cancer cell lines, in order to determine
whether my compounds are active
against telomerase. Their efficacy will be
compared against BIBR 1532 itself, as
well as other known telomerase inhibitors.
The compounds will also be tested to
determine if it has the ability to destroy
cancer cells, while leaving healthy cells
untouched. If one of these compounds
is found to be more effective at fighting
cancer then BIBR 1532, it would open
doors to a newer and safer drug
treatment program.
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